Trial Profile

A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CUSP-06 (Primary)
Indications Ovarian cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors OnCusp Therapeutics

Most Recent Events

14 Apr 2026 Planned number of patients changed from 263 to 376.
02 Jun 2025 According to an OnCusp Therapeutics media release, data support continued evaluation of CUSP06 in platinum-resistant HGSOC and other CDH6-positive tumors in Phase 1b expansion cohorts.
02 Jun 2025 Results presented in an OnCusp Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com